Brokerages expect that Applied DNA Sciences, Inc. (NASDAQ:APDN) will announce ($0.18) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Applied DNA Sciences’ earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.24). Applied DNA Sciences posted earnings per share of ($0.79) in the same quarter last year, which would indicate a positive year over year growth rate of 77.2%. The company is expected to report its next earnings report on Thursday, May 13th.
On average, analysts expect that Applied DNA Sciences will report full year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.88) to ($0.44). For the next fiscal year, analysts anticipate that the company will post earnings of $0.63 per share, with EPS estimates ranging from $0.40 to $0.85. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Applied DNA Sciences.
Applied DNA Sciences (NASDAQ:APDN) last announced its quarterly earnings results on Wednesday, February 10th. The technology company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.02). The business had revenue of $1.62 million for the quarter, compared to analyst estimates of $1.40 million. Applied DNA Sciences had a negative net margin of 672.79% and a negative return on equity of 179.48%.
APDN stock traded down $0.49 during midday trading on Friday, reaching $7.74. 6,990 shares of the company’s stock traded hands, compared to its average volume of 1,494,628. The company has a market capitalization of $57.84 million, a P/E ratio of -2.25 and a beta of 1.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.13 and a quick ratio of 2.01. Applied DNA Sciences has a fifty-two week low of $3.61 and a fifty-two week high of $16.39. The business has a 50-day moving average price of $8.66 and a two-hundred day moving average price of $8.12.
Large investors have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new stake in shares of Applied DNA Sciences in the third quarter worth $78,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Applied DNA Sciences in the third quarter worth $84,000. Orion Portfolio Solutions LLC acquired a new position in Applied DNA Sciences in the fourth quarter worth $65,000. Golden Green Inc. acquired a new position in Applied DNA Sciences in the fourth quarter worth $70,000. Finally, GSA Capital Partners LLP acquired a new position in Applied DNA Sciences in the fourth quarter worth $186,000. Institutional investors and hedge funds own 7.04% of the company’s stock.
About Applied DNA Sciences
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.